[go: up one dir, main page]

AR052837A1 - Composiciones que contienen hierro - Google Patents

Composiciones que contienen hierro

Info

Publication number
AR052837A1
AR052837A1 ARP050105442A ARP050105442A AR052837A1 AR 052837 A1 AR052837 A1 AR 052837A1 AR P050105442 A ARP050105442 A AR P050105442A AR P050105442 A ARP050105442 A AR P050105442A AR 052837 A1 AR052837 A1 AR 052837A1
Authority
AR
Argentina
Prior art keywords
iron
compositions
nutritional
promote
approximately
Prior art date
Application number
ARP050105442A
Other languages
English (en)
Inventor
Jonathan D Bortz
David S Hermelin
Mitchell I Kirschner
Original Assignee
Drug Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Tech Corp filed Critical Drug Tech Corp
Publication of AR052837A1 publication Critical patent/AR052837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)

Abstract

Composiciones de suplementos nutricionales o dietarios que promueven y/o mantienen la absorcion de hierro por la dieta mediante la administracion de hierro con un ácido orgánico y opcionalmente con promotores similares de la absorcion de hierro. Se proveen además métodos de suplementacion nutricional o dietaria utilizando una o más composiciones que promueven y/o mantienen la salud mediante la prevencion, estabilizacion, reversion y/o tratamiento de enfermedades asociadas con la deficiencia de hierro. Reivindicacion 1: Una composicion, caracterizada porque comprende: entre aproximadamente 10 mg. y aproximadamente 500 mg. de una o más formas de hierro; y entre aproximadamente 5 mg. y aproximadamente 500 mg. de una o más formas de un ácido orgánico, para administrar y así prevenir, estabilizar, revertir o tratar enfermedades relacionadas con la deficiencia de hierro en humanos u otros animales.
ARP050105442A 2004-12-22 2005-12-21 Composiciones que contienen hierro AR052837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/020,801 US20060134227A1 (en) 2004-12-22 2004-12-22 Compositions including iron

Publications (1)

Publication Number Publication Date
AR052837A1 true AR052837A1 (es) 2007-04-04

Family

ID=36596132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105442A AR052837A1 (es) 2004-12-22 2005-12-21 Composiciones que contienen hierro

Country Status (11)

Country Link
US (5) US20060134227A1 (es)
EP (2) EP1827418A4 (es)
JP (2) JP2008525442A (es)
CN (1) CN101102762A (es)
AR (1) AR052837A1 (es)
AU (1) AU2005319679A1 (es)
BR (1) BRPI0519265A2 (es)
CA (1) CA2591996A1 (es)
MX (1) MX2007008021A (es)
PE (1) PE20061122A1 (es)
WO (2) WO2006068697A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
WO2007035760A1 (en) * 2005-09-20 2007-03-29 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
ES2380952T3 (es) * 2005-10-11 2012-05-21 Bayer Consumer Care Ag Mezcla de sales de hierro y cobre que enmascaran el sabor metálico.
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
CA2953964A1 (en) 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP2073821B1 (en) * 2006-09-28 2012-10-24 Bayer Consumer Care AG Mixture of iron and copper salts masking metallic taste
CN101742998B (zh) * 2007-03-22 2014-09-17 玛格塞蒂克斯公司 镁组合物及其用途
US8163301B2 (en) 2007-03-22 2012-04-24 Magceutics, Inc. Magnesium compositions and uses thereof for metabolic disorders
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US20090047362A1 (en) * 2007-08-13 2009-02-19 Keith Edward Forrester Method for in-vitro stabilization of heavy metals
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
US20090124572A1 (en) * 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
WO2009158032A1 (en) 2008-06-25 2009-12-30 Fe2, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
US20110244057A1 (en) * 2008-09-25 2011-10-06 Ehrenberg Bruce L Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US8202830B2 (en) 2009-01-30 2012-06-19 Ecolab Usa Inc. Development of an aluminum hydroxydicarboxylate builder
MX2011007324A (es) * 2009-01-30 2011-08-12 Ecolab Inc Desarrollo de un aditivo de hidroxicaboxilato de aluminio.
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
WO2010136839A1 (en) * 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
JP5357102B2 (ja) * 2010-04-27 2013-12-04 日本炉機工業株式会社 石化遺骨灰の製造方法
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
IT1402142B1 (it) * 2010-09-24 2013-08-28 Just Pharma S R L Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche.
EP2497380A1 (en) * 2011-03-10 2012-09-12 DSM IP Assets B.V. Process for iron supplementation of beverages
ES2548407T3 (es) 2011-05-31 2015-10-16 Vifor (International) Ag Compuestos de complejos de 2,4-dioxo-1-carbonilo de Fe(III) para su uso en el tratamiento y la profilaxis de estados de deficiencia de hierro y anemias por deficiencia de hierro
WO2013044246A1 (en) 2011-09-22 2013-03-28 Amip Buffered upper gi absorption promoter
WO2013192565A2 (en) * 2012-06-21 2013-12-27 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
JP6573551B2 (ja) * 2012-09-11 2019-09-11 クーラ グローバル ヘルス（ビーブイアイ）リミティド 鉄を含有する栄養補助剤
CN102961338B (zh) * 2012-12-07 2015-03-18 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
CA2913413C (en) * 2013-06-06 2021-11-23 Amip, Llc Iron supplement
JP6566270B2 (ja) * 2013-08-28 2019-08-28 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． ブイヨン濃縮物の鉄補給
JP6484896B2 (ja) * 2013-08-28 2019-03-20 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． ブイヨン濃縮物の鉄補給
CN104955452B (zh) * 2013-09-05 2017-06-09 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
JP2014051535A (ja) * 2013-12-19 2014-03-20 Fujifilm Corp 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
EP3179249A4 (en) * 2014-08-05 2017-07-26 Fujifilm Corporation Nucleated erythrocyte sorting method
EP3179870B1 (en) 2014-08-13 2023-10-04 Akeso Biomedical Inc. Antimicrobial compounds and compositions, and uses thereof
GB201416293D0 (en) * 2014-09-15 2014-10-29 Solvotrin Therapeutics Ltd Methods and preparations
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
US10913705B2 (en) * 2014-11-07 2021-02-09 Npa—Núcleo De Pesquisas Aplicadas Ltda Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
US10183040B2 (en) 2014-12-01 2019-01-22 Profeat Biotechnology Co., Ltd. Method for regulation of lipid metabolism
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN108024563A (zh) 2015-08-11 2018-05-11 艾索生物医药公司 提高家畜中重量增加的生物膜抑制组合物
CN105476953B (zh) * 2015-09-01 2018-10-30 张伟 一种用于补铁的液体制剂及其制备方法
BR112018004244A2 (pt) * 2015-09-04 2018-09-25 Rockwell Medical Inc formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso
JP6919117B2 (ja) * 2015-12-15 2021-08-18 三菱ケミカル株式会社 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP3199167A1 (de) * 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
AU2017232266B2 (en) * 2016-03-15 2022-10-06 Solvotrin Therapeutics Ltd Compositions and methods for increasing iron intake in a mammal
WO2017200415A1 (ru) * 2016-05-20 2017-11-23 Общество с ограниченной ответственностью "ВИК-здоровье животных" Инъекционная композиция комплекса железо декстрана с витаминами для профилактики и лечения анемий
CA3023964A1 (en) * 2016-05-26 2017-11-30 Profeat Biotechnology Co., Ltd. Use of composition comprising ferrous amino acid chelate for manufacture of medicine for reducing lactic acid
CN106265731B (zh) * 2016-09-30 2019-07-19 广西科技大学 硫酸亚铁骨架型缓释滴丸的制备方法
CN110198709A (zh) * 2017-02-17 2019-09-03 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造治疗肝功能异常的医药品的用途
KR20200044030A (ko) * 2017-09-11 2020-04-28 파르마코스모스 홀딩 에이/에스 치료용 철 착화합물
CN108635370A (zh) * 2018-07-13 2018-10-12 山东达因海洋生物制药股份有限公司 一种含有右旋糖酐铁的组合物制剂及其制备方法
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
EP3860621A4 (en) * 2018-10-05 2022-07-06 Ampersand Biopharmaceuticals, Inc. IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY
US20210393678A1 (en) * 2018-10-31 2021-12-23 My-Or Diagnostics Ltd. Personalized food products for ensuring adequate iron intake
WO2020124495A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁氨基酸粒子的组合物及其用于制造治疗或改善胰脏相关疾病的医药品的用途
WO2020125462A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓神经受损相关疾病的医药品的用途
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
US12441615B2 (en) 2021-02-11 2025-10-14 Thermolife International, Llc Method of administering nitric oxide gas
US12059399B2 (en) * 2021-06-30 2024-08-13 Getwing Biotechnology Medical Co., Ltd Methods for alleviating kidney disease and fibrosis of organ
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法
WO2023023029A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用
CN114288320A (zh) * 2021-12-29 2022-04-08 珠海天翼医药技术开发有限公司 一种猪用口服补铁剂及其制备方法
CN114767710B (zh) * 2022-04-12 2023-07-07 中山大学 甘氨酸亚铁在治疗类风湿关节炎中的应用
CN116636620B (zh) * 2023-05-25 2025-02-14 南昌大学 一种乌鸡蛋清肽组合物及其应用
WO2026017897A1 (en) 2024-07-18 2026-01-22 Malian Biologicals Gmbh Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB1266356A (es) * 1968-08-08 1972-03-08
GB1292820A (en) * 1969-08-28 1972-10-11 Aspro Nicholas Ltd Haematinic preparations
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US3773929A (en) * 1972-11-02 1973-11-20 Diagnostic Data Inc Pharmaceutical compositions comprising orgotein and their use
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4599152A (en) * 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US4830716B1 (en) * 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
FR2642420B1 (fr) * 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5662922A (en) * 1992-01-20 1997-09-02 Christensen; Borge Holm Iron-containing composition for the prevention of anaemia and a method for producing the composition
US5516925A (en) * 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
JP2590449B2 (ja) * 1995-04-21 1997-03-12 農林水産省畜産試験場長 新生子牛の造血機能の改善及び貧血の予防方法
CA2235618C (en) * 1995-10-27 2002-09-03 William John Henry Jr. Color stable iron, zinc and vitamin fortified dry drink mixes
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
CA2230801A1 (en) * 1998-02-27 1999-08-27 Stanley H. Zlotkin Composition comprising micro-encapsulated iron
US6495177B1 (en) * 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
CN1396908A (zh) * 2000-01-28 2003-02-12 宝洁公司 美味的精氨酸化合物及其用于心血管健康的应用
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6716814B2 (en) * 2001-08-16 2004-04-06 Albion International, Inc. Enhancing solubility of iron amino acid chelates and iron proteinates
US6906038B2 (en) * 2001-08-29 2005-06-14 Abbott Laboratories Methods for alleviating mucositis
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
US7994217B2 (en) * 2002-05-02 2011-08-09 Xanodyne Pharmaceuticals, Inc. Prenatal multivitamin/multimineral supplement
AU2003246644A1 (en) * 2002-07-08 2004-01-23 Genova, Ltd. Secreted peptides
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
US8007846B2 (en) * 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility

Also Published As

Publication number Publication date
EP1827419A4 (en) 2011-08-17
US20130189374A1 (en) 2013-07-25
AU2005319679A1 (en) 2006-06-29
US20160022631A1 (en) 2016-01-28
WO2006068697A2 (en) 2006-06-29
JP2008525445A (ja) 2008-07-17
WO2006068729A2 (en) 2006-06-29
BRPI0519265A2 (pt) 2009-01-06
EP1827419A2 (en) 2007-09-05
PE20061122A1 (es) 2006-10-16
WO2006068697A3 (en) 2006-12-21
JP2008525442A (ja) 2008-07-17
EP1827418A4 (en) 2011-08-24
EP1827418A2 (en) 2007-09-05
US20060134227A1 (en) 2006-06-22
CN101102762A (zh) 2008-01-09
MX2007008021A (es) 2008-04-11
US20090028962A1 (en) 2009-01-29
WO2006068729A3 (en) 2007-01-18
CA2591996A1 (en) 2006-06-29
US20110015150A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
AR052837A1 (es) Composiciones que contienen hierro
MXPA04009765A (es) Metodo para mejorar la absorcion de la vitamina e por una mascota animal.
ATE508642T1 (de) Hydroxytyrosol-verstärkte öle und deren verwendung
AR064332A1 (es) Composicion suplementaria nutricional o dietetica que fortalece y promueve la salud retinal
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
PT1957061E (pt) Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular
MX2016006147A (es) Suplemento alimenticio.
MX2010004113A (es) Composicion para regular el metabolismo de lipidos.
TW200420288A (en) Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
PT1411960E (pt) Produto alimentar enriquecido a base de farelo de arroz para promocao da saude cardiovascular
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
CY1112660T1 (el) Συμπληρωμα διατροφης που παρεχει ενεργεια σε σκελετικους μυες και που προστατευει την καρδιαγγειακη οδο
BRPI0600199A (pt) usos de ácido pinolênico ou um seu derivado e de uma composição
CL2023002451A1 (es) Composiciones y métodos que usan una combinación de oleuropeína y vitamina b6
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
BR0210906A (pt) Método para aumento de eficiência de ruminantes
AR114427A1 (es) Una composición de alimento para rumiantes que comprende polipéptidos que tienen actividad de muramidasa y métodos para mejorar la digestibilidad en rumiantes
WO2007002837A3 (en) Methods and compositions for the prevention and treatement of inflammatory disease
CL2023002452A1 (es) Composiciones y métodos que usan una combinación de oleuropeína y magnesio
NO20081791L (no) Kombinasjon av metionin og minst ±n eterisk olje
MX2025002883A (es) Metodos para proporcionar beneficios para la salud en animales
RU2013133998A (ru) Способы и композиции для предотвращения и лечения остеоартрита
AR076576A1 (es) Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür

Legal Events

Date Code Title Description
FB Suspension of granting procedure